OC
AEGR

Oppenheimer & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

Oppenheimer & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-48,150
Closed -$1.01M – 1578
2014
Q4 		$1.01M Buy
48,150
+31,250
+185% +$787K 0.03% 601
2014
Q3 		$564K Buy
+16,900
New +$525K 0.02% 804

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oppenheimer & Co's AEGR Position: Q1 2015 in Review

Oppenheimer & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2015, closing a stake of 48,150 shares — an estimated $1.01M sold.

Oppenheimer & Co first reported a position in AEGR in Q3 2014 and held it in 2 quarters. The position peaked at $1.01M in Q4 2014. 99 funds tracked by Wall St. Rank hold AEGR as of Q1 2015.

  • Oppenheimer & Co reported no remaining Aegerion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 48,150 Aegerion Pharmaceuticals shares in Q1 2015, an estimated $1.01M.
  • Oppenheimer & Co first reported a position in Aegerion Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Oppenheimer & Co's Aegerion Pharmaceuticals position peaked at $1.01M in Q4 2014.
  • 99 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2015.

Based on Oppenheimer & Co's 13F filing for Q1 2015, filed 8 May 2015.